Companies

View our portfolio of investments

The cumulative expertise of the Cardinal Partners spans multiple industry sub-sectors. As early/growth-stage investors with deep experience and superior investment returns we have demonstrated that we know how to successfully build durable, valuable companies throughout multiple business and economic cycles.

QPID Artificial Intelligence (AI) software uses NLP and machine learning to generate fact from medical records for CDS, CCM and Quality Reporting. Cardinal Partners was a participant in “spin-out” financing from Partners HealthCare. QPID Health was acquired by eviCore healthcare, a leading medical benefits management company.

Biopharmaceutical research based on research associated with sirtuin enzymes, with eventual application in diseases associated with aging, such as Type 2 Diabetes. In humans. IPO in 2006, acquired by GSK in 2007. CHP II was founding investor.

Revolutionary infusion pump technology based on pneumatics rather than mechanics with huge safety / clinical / economic benefits for payors, providers, patients.
Cardinal Partners is founding investor providing regulatory planning, investor syndicate and strategic partnering.

Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA. In 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion) as entree to the market for drugs that can combat superbugs.

Web-based physician directory / decision-support tool. The largest online database of patient reviews for doctors and facilities. Sapphire-Digital has developed a SmartShopper tool that helps consumers navigate services with a concierge system to find high quality, lower cost providers. Acquired by Zelis in Sep, 2021.

The premier outsource provider of medical billing, practice management, and EMR services for physicians. CHP I/II was first VC termsheet, Co-led first round. Most successful IPO of 2007. On February 15, 2022, the company was acquired by Bain Capital for $17 billion.

The HIPAA secure group messaging system created by healthcare providers for healthcare providers. Cureatr provides group messaging apps for healthcare providers to overcome care-coordination challenges that result in delays and errors.

Privia Health is a national physician practice management and population health technology company (ACO -accountable care organization), providing next-generation physician-centric management services and insurance products.

Prealize Health formerly Cardinal Analytx Solutions, a developer of advanced machine learning solutions for improving healthcare while reducing costs by predicting impending medical conditions. Cardinal Partners is founding investor.

National (and International) Leader in Telehealth Services: “medicine to the masses”, providing doctor consults to consumers. Speak to a licensed doctor by web, phone or mobile app in minutes. Cardinal Partners is lead investor, raising capital and IPO process, assisting with strategic partnerships and M&A.

Verastem is focusing on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways. These signaling pathways are abnormal in cancer and promote tumor survival. Preclinical research has shown these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of existing cancer treatments.

Cloud based medical imaging sharing platform for hospitals, physicians and patients. CHP III lead 2nd round financing.Founded in 2008, Life Image has spent the past decade innovating an interoperable network ecosystem that connects hospitals, physicians, patients, life sciences, medical device companies, telehealth companies, and EHRS.

Natural Language Processing for computer-assisted coding of medical dictation notes for medical billing. Data mining and decision support tools also under development. CHP II invested in first institutional round. Acquired by 3M Health Information Systems in April 2012.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. CHP II was founding investor, IPO in 2004.

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Drug discovery based on glycomics, (the study of complex sugars) Groundbreaking application in the area of developing generic biologics. CHP II was founding investor, June 2004 IPO. Co-Investors: Polaris, Atlas, MVM, Mithra.

Novel drug development platform targeting central nervous system diseases. Platform has generated dozens of drug leads with clinical trials underway in Tourette’s Syndrome, MS and Agitation in Alzheimer’s Patients. Cardinal Partners is founding investor. May 2019 – Acquired by Denmark’s H. Lundbeck A/S.

Vividion is a next generation biotechnology company focused on expanding the therapeutic potential of small molecules. Drug development technology platform for a broad array of protein targets that have heretofore been deemed ‘undruggable’. CHP III is founding investor. August 2021 – acquired by Bayer AG for $2 billion.

aTyr Pharma is a public biotherapeutics company that researches and develops Physiocrine-based therapeutics for treatment of rare diseases with an immune component.. CHP III was initial investor, incubated at Cardinal.

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc